Monitor for additional Form 144 or Form 4 filings from Kapadia and other insiders. The sustained selling pattern by a former officer over the past six weeks is a negative signal. Watch next earnings for any fundamental deterioration that might explain the insider reduction.
Price Chart
Executive Summary
Former officer Sandip Kapadia filed a Form 144 notice of intent to sell 4,406 shares of Harmony Biosciences common stock, valued at approximately $154,302, via Morgan Stanley. The shares were acquired through option exercises under a registered plan. Kapadia has sold a total of 82,606 shares since early May 2026, representing a meaningful reduction of his position.
Key Facts
- Former officer Sandip Kapadia filed Form 144 on 2026-06-24 to sell 4,406 shares (~$154,302).
- Shares were acquired via exercise of options under a registered plan on the same date.
- Kapadia has sold 82,606 shares total since May 8, 2026, including 27,960 on 6/9, 2,101 on 6/5, 7,064 on 6/4, and 45,481 on 5/8.
- The filing does not disclose Kapadia's remaining holdings, but the cumulative sales since May 8 represent a significant insider reduction.
- The stock trades on Nasdaq under ticker HRMY with a $2.0B market cap.
Financial Impact
Proposed sale of 4,406 shares at ~$154,302; cumulative insider sales of 82,606 shares since May 8, 2026.
Risk Factors
- Insider selling may indicate lack of confidence in near-term prospects or upcoming negative catalyst.
- Further insider sales could pressure the stock price.
- The selling is by a former officer, which may be part of routine post-employment diversification, but the volume and timing are notable.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006445 |
| Document: 0001950047-26-006445-index.html | 0001950047-26-006445 |
| Document: 0001950047-26-006445.txt | 0001950047-26-006445 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Aug 4, 2026 8w ago | Press Release | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Jul 16, 2026 11w ago | 8-K | $33.53 $35.80 | ▲ +6.77% | ▲ +8.44% | $40.53 (+20.89%) |
Jun 30, 2026 13w ago | 144 | $36.00 $38.26 | ▼ −6.28% | ▼ −6.02% | $40.53 (−12.60%) |
Jun 24, 2026 14w ago | 144 | $34.13 $36.00 | ▼ −5.48% | ▼ −3.92% | $40.53 (−18.77%) |
Jun 9, 2026 16w ago | 144 | $35.48 $33.83 | ▼ −4.65% | ▼ −8.08% | $40.53 (+14.25%) |
Jun 5, 2026 16w ago | 144 | $32.39 $34.18 | ▲ +5.53% | ▲ +3.41% | $40.53 (+25.15%) |
May 19, 2026 19w ago | 3 | $30.44 $30.76 | ▲ +1.05% | ▼ −1.25% | $40.53 (+33.16%) |
May 7, 2026 21w ago | 8-K | $31.42 $30.83 | ▼ −1.88% | ▼ −3.38% | $40.53 (+29.01%) |
Apr 14, 2026 24w ago | 8-K | $29.29 $32.14 | ▲ +9.73% | ▲ +8.34% | $40.53 (+38.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access